Whilst Lightlake Therapeutics' primary focus is to investigate the use of our opioid antagonist
nasal spray for obese and overweight patients with Binge Eating Disorder, our research suggests our proprietary technology can be extended to treat other conditions including drug dependency, overdose, and Bulimia Nervosa.
Access to opioid antagonists
empowers community members to effectively respond during an overdose emergency and increases the likelihood that individuals struggling with addiction can be directed to treatment resources.
For these reasons, clinicians should be aware that the commonly used opioid antagonist
naloxone can produce false-positive opiate immunoassay results.
A similar study and similar result was obtained in a study using another opioid antagonist
, Naltrexone (11).
Withdrawal also may be precipitated through the administration of drugs with opioid antagonist
EVZIO is an opioid antagonist
indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
The Company is also announcing the launch of a proof-of-concept research program related to its opioid antagonist
patents for the treatment of cocaine, amphetamine and ecstasy abuse and addiction.
In the third quarter of 2011, Lightlake commenced Phase II trials in Helsinki, Finland, to investigate the use of the opioid antagonist
naloxone intra-nasally as a treatment for Binge Eating Disorder, which is the most common eating disorder in the US today
Buprenorphine, combined with the opioid antagonist
naloxone (Suboxone), will be used as maintenance therapy Naloxone is relatively ineffective by mouth, but if this formulation is injected intravenously, naloxone will precipitate an immediate and severe withdrawal.
OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company using its expertise of opioid antagonists
to develop modern addiction treatments, announced today that it will conduct Phase II trials at King's College London on an opioid antagonist
-based nasal spray treatment for Bulimia Nervosa.
In two-thirds of cases, the opioid antagonist
was administered by a friend, in 14% by a partner or family member, and in 9% by a stranger.
Presurgical administration of the investigational opioid antagonist
ADL 8-2698 to patients undergoing abdominal surgery shortened the duration of subsequent ileus and hospitalization, reported Dr.